Newsletter
Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

JAMA Editor’s Summary

Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

May 09, 2017 edition of the weekly JAMA Editors' Summary
May 9, 2017

Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

May 09, 2017 edition of the weekly JAMA Editors’ Summary

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
What Will Variant Sigma Look Like? with Michael T. Osterholm, Ph.D., Regents Professor, Division of Environmental Health Science; Director, Center for Infectious Disease Research and Policy (CIDRAP) University of Minnesota